NCT01934192 - Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2014

Primary Completion Date

July 8, 2016

Study Completion Date

July 8, 2016

Conditions

Gastroparesis

Interventions

DRUG

GSK962040 50 mg

GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.

DRUG

Metoclopramide 10 mg

Metoclopramide will be administered IV every 6 h

DRUG

Placebo NG

Matching placebo once daily enteral dose will be administered through NG tube up to 7 days

DRUG

Placebo IV

Placebo will be administered IV every 6 hours

Trial Locations (19)

2031

GSK Investigational Site, Randwick

4215

GSK Investigational Site, Southport

5000

GSK Investigational Site, Adelaide

5011

GSK Investigational Site, Woodville

19104

GSK Investigational Site, Philadelphia

30909

GSK Investigational Site, Augusta

40202

GSK Investigational Site, Louisville

80045

GSK Investigational Site, Aurora

T1Y 6J4

GSK Investigational Site, Calgary

T2N 2T9

GSK Investigational Site, Calgary

L8L 2X2

GSK Investigational Site, Hamilton

K7L 2V7

GSK Investigational Site, Kingston

K1H 8L6

GSK Investigational Site, Ottawa

K1Y 4E9

GSK Investigational Site, Ottawa

M5G 1X5

GSK Investigational Site, Toronto

H2X 3J4

GSK Investigational Site, Montreal

G1J 1Z4

GSK Investigational Site, Québec

G1V 4G5

GSK Investigational Site, Sainte-Foy

J1H 5N4

GSK Investigational Site, Sherbrooke